New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2013
05:55 EDTRHHBY, RHHBY, JNJ, JNJ, AMGN, AMGN, CELG, CELG, BIIB, BIIB, RGLS, RGLS, MRK, MRK, NVS, NVS, GSK, GSK, BMY, BMYBiocom to host a conference
3rd Annual Global Life Science Partnering Conference is being held in San Diego, California on February 27-28.
News For BMY;GSK;NVS;MRK;RGLS;BIIB;CELG;AMGN;JNJ;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
April 8, 2015
07:33 EDTMRKAdvaxis, Merck begin enrollment in Phase 1/2 of ADJX-PSA with Keytruda
Advaxis (ADXS) and Merck (MRK) announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA, an investigational Lm-LLO immunotherapy, and Keytruda, the first anti-PD-1 therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer, or mCRPC. The clinical trial, KEYNOTE-046, is the first-in-human study of Advaxis's lead Lm-LLO immunotherapy candidate for prostate cancer. It is the second study initiated to evaluate the use of KEYTRUDA in the treatment of advanced prostate cancer. ADXS-PSA and KEYTRUDA are members of a class of cancer treatments known as immuno-oncology therapies. Data from preclinical studies suggest that Advaxis Lm-LLO immunotherapies in combination with a PD-1 antibody may lead to an enhanced anti-tumor immune response. The results from KEYNOTE-046 will determine the future clinical development program for the combination.
07:24 EDTBIIB, JNJNeurotechnology Industry Organization to hold a conference
Subscribe for More Information
07:04 EDTMRKMerck's investigational Hep C therapy granted breakthrough therapy designations
Subscribe for More Information
April 7, 2015
19:10 EDTRGLSOn The Fly: After Hours Movers
Subscribe for More Information
16:12 EDTRGLSRegulus up 5% after RG-125 selected as clinical candidate by AstraZeneca
Subscribe for More Information
16:12 EDTRGLSRegulus RG-125 selected as clinical candidate by AstraZeneca
Regulus Therapeutics (RGLS) announced the selection of RG-12, a GalNAc-conjugated anti-miR targeting microRNA-103/107, or miR-103/107, for the treatment of Non Alcoholic Steatohepatitis, or NASH, in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca (AZN) under the companies' strategic alliance to discover, develop and commercialize microRNA therapeutics. RG-125 is the first compound from the alliance to be selected for clinical development by AstraZeneca. In connection with the candidate selection, AstraZeneca will pay Regulus $2.5M and will assume development of the program following acceptance of an Investigational New Drug application. In the near term, Regulus and AstraZeneca plan to submit key preclinical data on the RG-125 program to be presented at a scientific meeting later this year and expect to initiate a Phase I study of RG-125 in humans by the end of 2015.
07:31 EDTBIIBBiogen to present data on neurological disease therapies at AAN meeting
Subscribe for More Information
07:24 EDTCELGCelgene Otezla has growing opportunity, says Bernstein
After interviewing small groups of New York City area dermatologists, Bernstein believes that Celgene's psoriasis,treatment, Otezla, has a growing opportunity, due to its oral dosing, convenience, and lack of immunosuppression. The firm quotes doctors as saying that the drug serves as a useful "stepping stone," for patients who might need more intensive therapy, but want to postpone or avoid biologic Bernstein keeps a $158 price target and Outperform rating on Celgene.
07:14 EDTBIIB, MRK, RHHBY, GSK, BMY, NVSEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
April 6, 2015
16:17 EDTBMYOn The Fly: Closing Wrap
Subscribe for More Information
14:34 EDTJNJDepomed price target raised to $30 from $27 at Roth Capital
Subscribe for More Information
12:44 EDTBMYOn The Fly: Midday Wrap
Subscribe for More Information
12:13 EDTBMYuniQure price target raised to $40 from $35 at Piper Jaffray
Subscribe for More Information
09:36 EDTJNJActive equity options trading on open
Subscribe for More Information
08:13 EDTNVSJuno Therapeutics announces patent litigation settlement
Subscribe for More Information
08:13 EDTBMYCelldex announces initiation of Phase 1/2 study of Varlilumab combination
Subscribe for More Information
07:56 EDTRGLSAchillion price target lowered to $20 from $25 at Deutsche Bank
Subscribe for More Information
07:33 EDTBMYBristol-Myers announces strategic collaboration with uniQure
Subscribe for More Information
06:21 EDTJNJJohnson & Johnson CEO comments on Asia expansion, WSJ reports
Subscribe for More Information
05:19 EDTAMGNAmgen announces EC approval of Vectibix in combination with Folfiri
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use